TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›INDV›Financials
Annual statements · SEC XBRL · FY2022 – FY2025

Indivior Pharmaceuticals, Inc. (INDV) financials

Income statement

Indivior Pharmaceuticals, Inc. (INDV) income statement, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Revenue$901M$1.09B$1.19B$1.24B
Revenue growth—21.3%8.7%4.3%
Gross profit$749M$919M$957M$994M
Gross margin83.1%84.1%80.6%80.2%
Operating income-$81.0M-$152M$38.0M$262M
Operating margin-9.0%-13.9%3.2%21.1%
Net income-$44.0M-$126M$7.00M$210M
Net margin-4.9%-11.5%0.6%16.9%
EPS (diluted)-$0.32-$0.92$0.05$1.64

Cash flow

Indivior Pharmaceuticals, Inc. (INDV) cash flow, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Operating cash flow-$4.00M-$300M$36.0M-$27.0M
Capital expenditures$5.00M$8.00M$29.0M$66.0M
Free cash flow-$9.00M-$308M$7.00M-$93.0M
Share buybacks$90.0M$33.0M$173M$11.0M

Balance sheet

Indivior Pharmaceuticals, Inc. (INDV) balance sheet, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Cash & equivalents$774M$316M$319M$195M
Total assets—$1.76B$1.32B$1.20B
Total liabilities—$1.94B$1.65B$1.30B
Long-term debt—$237M$315M$290M
Shareholders' equity-$15.0M-$184M-$337M-$98.0M
Retained earnings—-$288M-$443M-$243M
Shares (wtd avg diluted)139M137M133M128M

Every figure is extracted from Indivior Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Indivior Pharmaceuticals, Inc.'s annual revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported $1.24B of revenue for fiscal year 2025 — up 4.3% from $1.19B in FY2024, per its annual report filed with the SEC.
Is Indivior Pharmaceuticals, Inc. profitable?
Yes — INDV earned $210M of net income in FY2025, a 16.9% net margin, per SEC filings.
What is Indivior Pharmaceuticals, Inc.'s free cash flow?
-$93.0M in FY2025 (operating cash flow -$27.0M minus $66.0M of capital expenditures), from the SEC cash-flow statement.
Does INDV pay a dividend?
Indivior Pharmaceuticals, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full INDV analysis — verdict, score & filings →Is INDV a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.